Literature DB >> 3624874

Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience.

B E Johansson, T M Moran, C A Bona, S W Popple, E D Kilbourne.   

Abstract

In man, vaccination with neuraminidase (NA) in H7N2 virus hybrids elicits greater anti-NA response than does N2 NA in H3N2 conventional vaccine, presumably because humans are H3 hemagglutinin (HA) primed and anti-H3 anamnestic response depresses concomitant N2 responses by antigenic competition. In a laboratory model, BALB/c mice were primed by different schedules of infection with H3N1, H3N2, and H3N7 viruses and given H3N2 and H7N2 vaccines equivalent in NA immunogenicity. In schedules using sequential infections, but not after a single infection with any virus, anti-N2 booster response was fourfold greater with H7N2 vaccine and was reciprocal to the magnitude of anti-H3 response. Thus, HA-influenced suppression of immunologic response to viral NA requires adequate HA priming but is not unique to man and can be studied in the murine model. An incidental finding of this study was the sharing of cross-reactive determinants by N1, N2, and N7 NA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3624874

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Antibody response to influenza infection of mice: different patterns for glycoprotein and nucleocapsid antigens.

Authors:  Robert Sealy; Sherri Surman; Julia L Hurwitz; Christopher Coleclough
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

2.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.

Authors:  B E Johansson; D J Bucher; E D Kilbourne
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

4.  Double-Layered M2e-NA Protein Nanoparticle Immunization Induces Broad Cross-Protection against Different Influenza Viruses in Mice.

Authors:  Ye Wang; Lei Deng; Gilbert X Gonzalez; Latika Luthra; Chunhong Dong; Yao Ma; Jun Zou; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Adv Healthc Mater       Date:  2019-12-15       Impact factor: 9.933

5.  Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition.

Authors:  B E Johansson; E D Kilbourne
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

6.  Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.

Authors:  Lisa Walz; Sarah-Katharina Kays; Gert Zimmer; Veronika von Messling
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

7.  Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.

Authors:  Esteban Cruz; Joel Cain; Ben Crossett; Veysel Kayser
Journal:  Hum Vaccin Immunother       Date:  2017-11-17       Impact factor: 3.452

8.  Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo.

Authors:  P A Scherle; W Gerhard
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

10.  Development of neuraminidase subtype-specific reference antisera by recombinant protein expressed in baculovirus.

Authors:  Kyu-Jun Lee; Jun-Gu Choi; Hyun-Mi Kang; Kwang-Il Kim; Choi-Kyu Park; Youn-Jeong Lee
Journal:  Clin Vaccine Immunol       Date:  2012-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.